Parallel Advisors
LRMR icon

Parallel Advisors’s Larimar Therapeutics LRMR Stock Holding History

Parallel Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-193
Closed -$869 – 4019
2026
Q1 		$869 Hold
193
– – ﹤0.01% 3563
2025
Q4 		$735 Buy
+193
New +$751 ﹤0.01% 3353

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Parallel Advisors's LRMR Position: Q2 2026 in Review

Parallel Advisors sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 193 shares — an estimated $869 sold.

Parallel Advisors first reported a position in LRMR in Q4 2025 and held it in 2 quarters. The position peaked at $869 in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Parallel Advisors reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Parallel Advisors sold 193 Larimar Therapeutics shares in Q2 2026, an estimated $869.
  • Parallel Advisors first reported a position in Larimar Therapeutics in Q4 2025 and held it in 2 quarters.
  • Parallel Advisors's Larimar Therapeutics position peaked at $869 in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.